research Efficacy of tofacitinib as an induction agent in severe alopecia areata compared to oral betamethasone weekly pulse
Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
Search
for
Sort by
Research
360-390 / 1000+ results 
research An unusual presentation of X-linked adrenoleukodystrophy
A man with X-ALD improved after treatment, highlighting the need to consider X-ALD in similar patients and test their relatives.
research 5PSQ-056 Experience with tofacinitib and baricitinib in rheumatoid arthritis
Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomised, double-blinded, placebo-controlled clinical trial
ALRV5XR significantly improves hair density in women with hair loss and is well-tolerated.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Diagnosed with primary adrenal insufficiency? search adrenoleukodystrophy-two brothers presented with similar phenotype
Two brothers from Bangladesh were diagnosed with X-linked adrenoleukodystrophy, showing neurological and adrenal symptoms.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Alopecia areata flare patterns in children and young adults while on systemic tofacitinib
Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
research A Promising Efficacy of Tofacitinib in an Adult Patient with Alopecia Areata
Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
research 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.
The treatment was not recommended due to limited effectiveness and significant side effects.
research 42577 Application of the new clinical guidelines in frontal fibrosing alopecia of the male
Current guidelines may overlook beard and sideburn involvement in diagnosing frontal fibrosing alopecia in men.
research Efficacy of Oral Tofacitinib in Alopecia Areata, Alopecia Totalis, and Alopecia Universalis
Tofacitinib significantly regrows hair in severe alopecia without major side effects.
research Successful treatment of alopecia totalis with tofacitinib in a Danish patient
A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
research Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
Baricitinib significantly improves hair regrowth in severe alopecia areata.
research Ferulic Acid Inhibits Catamenial Epilepsy Through Modulation of Female Hormones
Ferulic acid can reduce seizures and depression-like behaviors in catamenial epilepsy by balancing hormones and brain enzyme activity.
research Prevalence and treatment of Alopecia areata in Taif area, KSA
Alopecia areata in Taif is common, mainly immune-related, and best treated with topical corticosteroids and vitamins.
research 420 Alopecia in children and adults with cystic fibrosis on elexacaftortezacaftor-ivacaftor
research Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study
Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
research Serum Ferritin Level and Alopecia Areata in Pediatric Patients
Low serum ferritin levels are linked to more severe and longer-lasting alopecia areata in children.
research Forsythiaside A ameliorates sepsis-induced acute kidney injury via anti-inflammation and antiapoptotic effects by regulating endoplasmic reticulum stress
Forsythiaside A reduces kidney damage from sepsis by lowering inflammation and cell death.
research Effectiveness of oral tofacitinib treatment on patients with moderate‐to‐severe alopecia areata in Iran
Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
research Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
research Acute Diffuse and Total Alopecia of the Female Scalp
A new type of sudden, complete female hair loss was found, with most patients fully recovering within 6 months without needing steroid treatment.
research Frontal fibrosing alopecia: treatment with oral dutasteride and topical pimecrolimus
Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Comparison of Therapeutic Efficacy of Topical Tacrolimus 0.1% and Topical Dithranol 0.5% in Treatment of Alopecia Areata
Dithranol is more effective than Tacrolimus for hair regrowth in alopecia areata.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.